Cardurion Pharmaceuticals
PDE9/cardiac-signaling therapeutics for heart failure
Privately held: no public share price · United States
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | PDE9Small molecule | Heart Failure |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
11 October 2026Topline resultTovinontrineCycle-1 REF Phase 2: tovinontrine reduced NT-proBNP at 2.5 mg and 25 mg BID in HFrEF; no benefit at 50 mg BID
Cardurion Pharmaceuticals · Source ↗
11 October 2026Topline resultTovinontrineCycle-2 PEF Phase 2: no significant change in NT-proBNP with tovinontrine 50 mg BID in HFpEF
Cardurion Pharmaceuticals · Source ↗
Financial reports
No financial reports recorded.